Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
August 08, 2023 16:05 ET
|
Lyell Immunopharma, Inc
Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestonesRemain on track for initial clinical...
Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer
July 05, 2023 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
June 07, 2023 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
May 04, 2023 16:05 ET
|
Lyell Immunopharma, Inc
Two phase 1 clinical trials recruiting patients at 14 sites across the US; nine sites for LYL797, a ROR-1-targeted chimeric antigen receptor T cell (CAR-T) product candidate, and five sites for...
Lyell Immunopharma to Participate in BofA Securities Healthcare Conference
May 02, 2023 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
February 28, 2023 16:05 ET
|
Lyell Immunopharma, Inc
Cash, cash equivalents and marketable securities of $710.3 million as of December 31, 2022 supports advancing robust pipeline into 2026, through multiple clinical milestonesPhase 1 clinical trials...
Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
December 15, 2022 07:00 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma to Participate in BofA Securities Biotech Conference
December 01, 2022 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series
November 10, 2022 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...